Carlson JJ

No ORCID on file · 4 papers in corpus · active 2019-2023

Study types

  • other 1

Condition tags

  • endometriosis 1
other 2023
PharmacoEconomics ·doi:10.1007/s40273-022-01230-x

BACKGROUND: Current practice in health technology assessment (HTA) of pharmaceuticals conducts cost-effectiveness analyses (CEAs) based on a static price or the estimated price at market launch. Recent publications suggest incorporating dyn…

2020
Journal of managed care & specialty pharmacy ·doi:10.18553/jmcp.2020.26.8.962

BackgroundOvarian cancer is the tenth most common type of cancer and the fifth leading cause of cancer death among females in the United States. The majority of incident ovarian cancer cases are diagnosed in individuals aged < 65 years, but…

2020
Journal of managed care & specialty pharmacy ·doi:10.18553/jmcp.2020.26.12.1590

BACKGROUND: There has been growing interest in using real-world evidence (RWE) for health technology assessment (HTA) in the United States. The Institute for Clinical and Economic Review (ICER) is an independent U.S.-based HTA organization …

2019
PharmacoEconomics ·doi:10.1007/s40273-019-00832-2

Transparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the potential benefits of external access during model development and the need to protect intellectual property and …